Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts

Anticancer Research

Volumn 27, Issue 2, 2007, Pages 719-727

  Robertson, Fredika M ^a   Mallery, Susan R ^b,c   Bergdall Costell, Valerie K ^c   Cheng, Mark ^d,e   Pei, Ping ^c   Prosperi, Jenifer R ^c   Ferrari, Mauro ^a,d,e,f,g  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f Rice University   (United States)

^g Alliance for NanoHealth   (United States)

Author keywords

Angiogenesis; Cyclooxygenase 2; Ductal carcinoma; Human breast cancer model; Invasion; MCF 7 Cox 2 Clone 10; Xenografts

Indexed keywords

CYCLOOXYGENASE 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; BREAST DUCT; BREAST TUMOR; CELL CLONING; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD31; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 34247128314     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP and Robertson FM: Cyclooxygenase-2 gene expression in human breast cancer. Intl J Oncol 10: 503-507, 1997.
2. Hla T, Bishop-Bailey D, Liu CH, Schaefers HJ and Trifan OC: Cyclooxygenase-1 and -2 isoenzymes. Int J Biochem Cell Biol 31(5): 551-557, 1999. Review.
3. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J and Koki AT: COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89(12): 2637-2645, 2000.
4. Half E, Tang XM, Gwyn K, Sahin A, Wathen K and Sinicrope FA: Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62(6): 1676-1681, 2002.
5. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H and Isola J: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62(3): 632-635, 2002.
6. Parrett ML, Abou-Issa HM, Alshafie G, Ross MS, Harris RE and Robertson FM: Comparative ability of ibuprofen and N-(4- hydroxyphenyl)retinamide to inhibit development of rat mammary adenocarcinomas associated with differential inhibition of gene expression of cyclooxygenase isoforms. Anticancer Res 19(6B): 5079-5085, 1999.
7. Joarder FS, Abou-Issa H, Robertson FM, Parrett ML, Alshafie G and Harris RE: Growth arrest of DMBA-induced mammary carcinogenesis with ibuprofen treatment in female Sprague-Dawley rats. Oncol Reports 4: 1271-1273, 1997.
8. Robertson FM, Parrett ML, Joarder FS, Ross M, Abou-Issa HM, Alshafie G and Harris RE: Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas. Cancer Lett 122(1-2): 165-175, 1998.
9. Abbadessa G, Spaccamiglio A, Sartori ML, Nebbia C, Dacasto M, Di Carlo F and Racca S: The aspirin metabolite, salicylate, inhibits 7,12-dimethylbenz[a] anthracene-DNA adduct formation in breast cancer cells. Int J Oncol 28(5): 1131-1140, 2006.
10. Badawi AF, Eldeen MB, Liu Y, Ross EA and Badr MZ: Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma. Cancer Res 64(3): 1181-1189, 2004.
11. Retraction in: Cancer Res 65(17): 8057, 2005.
12. Kubatka P, Ahlers I, Ahlersova E, Adamekova E, Luk P, Bojkova B and Markova M: Chemoprevention of mammary carcinogenesis in female rats by rofecoxib. Cancer Lett 202(2): 131-136, 2003.
13. Jang TJ, Jung HG, Jung KH and MK O: Chemopreventive effect of celecoxib and expression of cyclooxygenase-1 and cyclooxygenase-2 on chemically-induced rat mammary tumours. Int J Exp Pathol 83(4): 173-182, 2002.
14. Singh-Ranger G and Mokbel K: The role of cyclooxygenase-2 (COX-2) in breast cancer, and implications of COX-2 inhibition. Eur J Surg Oncol 28(7): 729-737, 2002.
15. Kubatka P, Kalicka K, Chamilova M, Ahlersova E, Ahlers I, Bojkova B and Adamekova E: Nimesulide and melatonin in mammary carcinogenesis prevention in female Sprague-Dawley rats. Neoplasma 49(4): 255-259, 2002.
16. Abou-Issa HM, Alshafie GA, Seibert K, Koki AT, Masferrer JL and Harris RE: Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. Anticancer Res 21(5): 3425-3432, 2001.
17. Nakatsugi S, Ohta T, Kawamori T, Mutoh M, Tanigawa T, Watanabe K, Sugie S, Sugimura T and Wakabayashi K: Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn J Cancer Res 91(9): 886-892, 2000.
18. Badawi AF and Archer MC: Effect of hormonal status on the expression of the cyclooxygenase 1 and 2 genes and prostaglandin synthesis in rat mammary glands. Prostaglandins Other Lipid Mediat 56(2-3): 167-181, 1998.
19. Kundu N and Fulton AM: Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res 62(8): 2343-2346, 2002.
20. Kundu N, Yang Q, Dorsey R and Fulton AM: Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer. Int J Cancer 93(5): 681-686, 2001.
21. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF and Hla T: Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276(21): 18563-18569, 2001.
22. Narko K, Zweifel B, Trifan O, Ristimaki A, Lane TF and Hla T: COX-2 inhibitors and genetic background reduce mammary tumorigenesis in cyclooxygenase-2 transgenic mice. Prostaglandins Other Lipid Mediat 76(1-4): 86-94, 2005.
23. Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC, Lane TF and Hla T: Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 101(2): 591-596, 2004.
24. Subbaramaiah K, Howe LR, Port ER, Brogi E, Fishman J, Liu CH, Hla T, Hudis C and Dannenberg AJ: HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism. Cancer Res 66(10): 5504-5511, 2006.
25. Howe LR, Chang SH, Tolle KC, Dillon R, Young LJ, Cardiff RD, Newman RA, Yang P, Thaler HT, Muller WJ, Hudis C, Brown AM, Hla T, Subbaramaiah K and Dannenberg AJ: HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res 65(21): 10113-10119, 2005.
26. Prosperi JR, Mallery SR, Kigerl KA, Erfurt AA and Robertson FM: Invasive and angiogenic phenotype of MCF-7 human breast tumor cells expressing human cyclooxygenase-2. Prostaglandins Other Lipid Mediat 73(3-4): 249-264, 2004.
27. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE and Robertson FM: Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 140(1-2): 27-35, 1999.
28. Prosperi JR and Robertson FM: Cyclooxygenase-2 directly regulates gene expression of P450 Cyp19 aromatase promoter regions pII, pI.3 and pI.7 and estradiol production in human breast tumor cells. Prostaglandins Other Lipid Mediat 81(1-2): 55-70, 2006.
29. Takahashi Y, Kawahara F, Noguchi M, Miwa K, Sato H, Seiki M, Inoue H, Tanabe T and Yoshimoto T: Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or -2. FEBS Lett 460(1): 145-148, 1999.
30. Dicken BJ, Graham K, Hamilton SM, Andrews S, Lai R, Listgarten J, Jhangri GS, Saunders LD, Damaraju S and Cass C: Lymphovascular invasion is associated with poor survival in gastric cancer: an application of gene-expression and tissue array techniques. Ann Surg 243(1): 64-73, 2006.
31. Byun JH, Lee MA, Roh SY, Shim BY, Hong SH, Ko YH, Ko SJ, Woo IS, Kang JH, Hong YS, Lee KS, Lee AW, Park GS and Lee KY: Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer. Jpn J Clin Oncol 36(5): 263-268, 2006.
32. Hanahan D, Christofori G, Naik P and Arbeit J: Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer 32A(14): 2386-2393, 1996.
33. Parangi S, O'Reilly M, Christofori G, Holmgren L, Grosfeld J, Folkman J and Hanahan D: Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 93(5): 2002-2007, 1996.
34. Affara NI and Robertson FM: Vascular endothelial growth factor as a survival factor in tumor-associated angiogenesis. In Vivo 18(5): 525-542, 2004.
35. Robertson FM and Ferrari M: Rationale for nanotechnology in cancer therapy. In: Nanotechnology for Cancer Therapy. Amiji MA (ed.). CRC Press, Taylor & Francis, Boca Raton, FL, pp. 3-10, 2007.